Proactive Investors - Run By Investors For Investors

Sienna Cancer Diagnostics achieves first sale of cancer test in Switzerland

The company’s in-vitro diagnostic test help urologists detect bladder cancer earlier.
cancer cells
Sienna listed on the ASX in 2017 after raising $4.6 million

Sienna Cancer Diagnostics Ltd (ASX:SDX) has achieved the first sale of its hTERT cancer test in Switzerland through its distribution partner, Biosystems Switzerland AG.

The company’s in-vitro diagnostic (IVD) hTERT test help urologists to detect bladder cancer earlier.

Sienna’s primary platform is the detection of the biomarker telomerase, which is found in nearly all epithelial cancers, and was the subject of a Nobel Prize in 2009.

Telomerase is well recognised as a remarkable biomarker used by 85% of cancers to enable immortal cell replication.

Clinical validation completed by the customer

Following the signing of Biosystems Switzerland as the exclusive distributor for Switzerland of Sienna’s novel IVD test, the first order by a Swiss laboratory has been delivered.

This follows training of Biosystems key personnel by Sienna in late 2017, and evaluation and clinical validation by the customer.

A biomarker test for diagnosing bladder cancer

Although urine cytology is non-invasive, it has significant limitations in terms of sensitivity, particularly when it comes to low-grade or early-stage bladder cancer.

Having a biomarker test that can provide additional clinically significant information for the diagnosing physician, while using the same urine sample collected for cytology, adds real value to the diagnostic process.

Biosystems Switzerland has generated a pipeline of interested laboratories, several of which are well advanced in evaluating the test for clinical use.

READ: Sienna Cancer Diagnostics to launch its in-vitro test in Denmark and Sweden

Sienna listed on the ASX in 2017 following a successful initial public offer (IPO) which raised $4.6 million.

The company achieved significant milestones in 2017, including FDA registration of its IVD product in the U.S. and CE Mark approval and IVD registration in the Europe Union.

Sienna’s near-term objective is to maximise growth opportunities in the U.S., with significant interest already shown by pathology laboratories in the hTERT test.

View full SDX profile View Profile

Sienna Cancer Diagnostics Ltd Timeline

Related Articles

scientist in lab
February 26 2019
Results from a 62-patient follow-up study are due shortly, while data from a 500-person-strong managed access programme should be available by the end of next year
scientist in a lab
April 12 2019
Danish giant Novo Nordisk recently signed up to use its NDD platform, and bosses expect more collaboration deals in the coming months
lung in x-ray
February 25 2019
The company has been developing a treatment for chronic lung disease in-house and has partnered with an Australian group to develop a drug for rare liver and lung complaints

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use